165 related articles for article (PubMed ID: 38236580)
21. Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.
Toulmonde M; Penel N; Adam J; Chevreau C; Blay JY; Le Cesne A; Bompas E; Piperno-Neumann S; Cousin S; Grellety T; Ryckewaert T; Bessede A; Ghiringhelli F; Pulido M; Italiano A
JAMA Oncol; 2018 Jan; 4(1):93-97. PubMed ID: 28662235
[TBL] [Abstract][Full Text] [Related]
22. Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma.
Livingston MB; Jagosky MH; Robinson MM; Ahrens WA; Benbow JH; Farhangfar CJ; Foureau DM; Maxwell DM; Baldrige EA; Begic X; Symanowski JT; Steuerwald NM; Anderson CJ; Patt JC; Kneisl JS; Kim ES
Clin Cancer Res; 2021 Dec; 27(23):6424-6431. PubMed ID: 34475102
[TBL] [Abstract][Full Text] [Related]
23. Factors predictive of second-line chemotherapy in soft tissue sarcoma: An analysis of the National Genomic Profiling Database.
Mochizuki T; Ikegami M; Akiyama T
Cancer Sci; 2024 Feb; 115(2):575-588. PubMed ID: 38115234
[TBL] [Abstract][Full Text] [Related]
24. FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen.
Osgood CL; Chuk MK; Theoret MR; Huang L; He K; Her L; Keegan P; Pazdur R
Clin Cancer Res; 2017 Nov; 23(21):6384-6389. PubMed ID: 28242632
[TBL] [Abstract][Full Text] [Related]
25. A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin.
Inagaki C; Shimoi T; Okuma H; Kitano A; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Yoshida A; Fujiwara Y; Tamura K
Anticancer Drugs; 2018 Jan; 29(1):97-101. PubMed ID: 29176397
[TBL] [Abstract][Full Text] [Related]
26. Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study.
Tolaney SM; Kalinsky K; Kaklamani VG; D'Adamo DR; Aktan G; Tsai ML; O'Regan RM; Kaufman PA; Wilks ST; Andreopoulou E; Patt DA; Yuan Y; Wang G; Savulsky C; Xing D; Kleynerman E; Karantza V; Diab S
Clin Cancer Res; 2021 Jun; 27(11):3061-3068. PubMed ID: 33727258
[TBL] [Abstract][Full Text] [Related]
27. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
29. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.
Keung EZ; Burgess M; Salazar R; Parra ER; Rodrigues-Canales J; Bolejack V; Van Tine BA; Schuetze SM; Attia S; Riedel RF; Hu J; Okuno SH; Priebat DA; Movva S; Davis LE; Reed DR; Reuben A; Roland CL; Reinke D; Lazar AJ; Wang WL; Wargo JA; Tawbi HA
Clin Cancer Res; 2020 Mar; 26(6):1258-1266. PubMed ID: 31900276
[TBL] [Abstract][Full Text] [Related]
30. Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial.
Pollack SM; Redman MW; Baker KK; Wagner MJ; Schroeder BA; Loggers ET; Trieselmann K; Copeland VC; Zhang S; Black G; McDonnell S; Gregory J; Johnson R; Moore R; Jones RL; Cranmer LD
JAMA Oncol; 2020 Nov; 6(11):1778-1782. PubMed ID: 32910151
[TBL] [Abstract][Full Text] [Related]
31. Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma.
Nathenson MJ; Barysauskas CM; Nathenson RA; Regine WF; Hanna N; Sausville E
World J Surg Oncol; 2018 Oct; 16(1):203. PubMed ID: 30309356
[TBL] [Abstract][Full Text] [Related]
32. Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis.
You Y; Guo X; Zhuang R; Zhang C; Wang Z; Shen F; Wang Y; Liu W; Zhang Y; Lu W; Hou Y; Wang J; Zhang X; Lu M; Zhou Y
Front Mol Biosci; 2021; 8():747650. PubMed ID: 34869583
[No Abstract] [Full Text] [Related]
33. Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours.
Mir O; Azaro A; Merchan J; Chugh R; Trent J; Rodon J; Ohnmacht U; Diener JT; Smith C; Yuen E; Oakley GJ; Le Cesne A; Soria JC; Benhadji KA; Massard C
Eur J Cancer; 2018 Nov; 103():88-97. PubMed ID: 30218977
[TBL] [Abstract][Full Text] [Related]
34. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
35. Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort.
Nishio M; Murakami S; Kawakami H; Okishio K; Tamiya M; Kobayashi H; Fujimoto D; Sugawara S; Kozuki T; Oya Y; Izumi H; Shiroyama T; Satouchi M; Yamamoto N; Kaname S; Matsuoka D; Otake Y; Takase T; Semba T; Azuma K
Cancer Res Commun; 2024 Jan; 4(1):226-235. PubMed ID: 38181055
[TBL] [Abstract][Full Text] [Related]
36. Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study.
Joshi M; Holder SL; Zhu J; Zheng H; Komanduri S; Warrick J; Yasin H; Garje R; Jia B; Drabick JJ; DeGraff DJ; Zakharia Y
Eur Urol Focus; 2022 Mar; 8(2):483-490. PubMed ID: 33741296
[TBL] [Abstract][Full Text] [Related]
37. Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study.
Blay JY; Schöffski P; Bauer S; Krarup-Hansen A; Benson C; D'Adamo DR; Jia Y; Maki RG
Br J Cancer; 2019 May; 120(11):1026-1032. PubMed ID: 31065111
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas.
Noujaim J; Alam S; Thway K; Jones RL
Indian J Med Paediatr Oncol; 2016; 37(3):125-30. PubMed ID: 27688604
[TBL] [Abstract][Full Text] [Related]
39. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.
Chi Y; Fang Z; Hong X; Yao Y; Sun P; Wang G; Du F; Sun Y; Wu Q; Qu G; Wang S; Song J; Yu J; Lu Y; Zhu X; Niu X; He Z; Wang J; Yu H; Cai J
Clin Cancer Res; 2018 Nov; 24(21):5233-5238. PubMed ID: 29895706
[No Abstract] [Full Text] [Related]
40. Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer.
Liu J; Wang Y; Tian Z; Lin Y; Li H; Zhu Z; Liu Q; Su S; Zeng Y; Jia W; Yang Y; Xu S; Yao H; Jiang W; Song E
Nat Commun; 2022 May; 13(1):3011. PubMed ID: 35641481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]